Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral administration of arsenic + ATRA effective for APML

Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Publish date:: July 13, 2018

Key clinical point: Acute promyelocytic leukemia can be effectively treated with a chemotherapy-free oral regimen.

Major finding: The 2-year event-free survival was 97% with oral arsenic/ATRA versus 94% with IV arsenic trioxide/ATRA.

Study details: Randomized open-label phase 3 trial of 109 patients with APML.

Disclosures: The National Natural Science Foundation of China, the Beijing Municipal Science and Technology Commission, and the National Key R&D Program of China supported the study. The investigators reported having no financial disclosures.

Source: Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Read the article.

Citation:

Zhu HH et al. Lancet Oncol. 2018;19:871-9.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,